webinar register page

Webinar banner
The Pros and Cons of Warfarin versus New Oral Anticoagulants (NOACs) #ACHACares
Some adult patients with congenital heart disease (CHD) take anticoagulants or blood thinners. Do you know why you might need this type of medicine? Do you want to learn more about warfarin and NOACs? Have you wondered how these drugs work and what drug interactions they might have? This webinar will explore what we know about the newer anticoagulants in CHD. It will also discuss the difference in anticoagulants and antiplatelet drugs. Register today so you don’t miss this webinar.

This webinar was made possible in part by an unrestricted educational grant from Janssen, Inc. Pharmaceutical Companies of Johnson & Johnson.

Apr 7, 2021 07:00 PM in Eastern Time (US and Canada)

* Required information

By registering, I agree to the Privacy Statement and Terms of Service.



David Gregg, MD
Director of the Adult Congenital Heart Disease (ACHD) Program @Medical University of South Carolina
Dr. Gregg serves on the Medical Advisory Board of the Adult Congenital Heart Association. He is also the director of the Adult Echocardiography lab at the Medical University of South Carolina. He publishes and lectures regularly on imaging in ACHD and multimodality imaging and is excited to talk with you about warfarin and new oral anticoagulants.